tradingkey.logo

DaVita Inc

DVA
查看詳細走勢圖
113.985USD
-0.425-0.37%
收盤 12/26, 16:00美東報價延遲15分鐘
8.09B總市值
11.49本益比TTM

DaVita Inc

113.985
-0.425-0.37%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-0.37%

5天

-1.05%

1月

-5.09%

6月

-19.54%

今年開始到現在

-23.78%

1年

-26.13%

查看詳細走勢圖

TradingKey DaVita Inc股票評分

單位: USD 更新時間: 2025-12-26

操作建議

DaVita Inc當前公司基本面數據相對穩定,增長潛力很大。當前估值合理,在醫療服務供應商行業排名41/78位。機構持股佔比非常高,近一個月多位分析師給出公司評級為持有。最高目標價138.59。中期看,股價處於下降通道。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

DaVita Inc評分

相關信息

行業排名
41 / 78
全市場排名
194 / 4563
所屬行業
醫療服務供應商

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 10 分析師
持有
評級
138.587
目標均價
+18.40%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

DaVita Inc亮點

亮點風險
DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.
利潤高增長
公司淨利潤處於行業前列,最新年度總收入12.82B美元
估值低估
公司最新PE估值11.49,處於3年歷史低位
機構加倉
最新機構持股36.29M股,環比增加0.04%
加拿大豐業銀行分紅基金持倉
明星投資者加拿大豐業銀行分紅基金持倉,最新持倉4.93K股

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

DaVita Inc簡介

DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.
公司代碼DVA
公司DaVita Inc
CEORodriguez (Javier J)
網址https://www.davita.com/

常見問題

DaVita Inc(DVA)的當前股價是多少?

DaVita Inc(DVA)的當前股價是 113.985。

DaVita Inc 的股票代碼是什麼?

DaVita Inc的股票代碼是DVA。

DaVita Inc股票的52週最高點是多少?

DaVita Inc股票的52週最高點是179.600。

DaVita Inc股票的52週最低點是多少?

DaVita Inc股票的52週最低點是113.120。

DaVita Inc的市值是多少?

DaVita Inc的市值是8.09B。

DaVita Inc的淨利潤是多少?

DaVita Inc的淨利潤為936.34M。

現在DaVita Inc(DVA)的股票是買入、持有還是賣出?

根據分析師評級,DaVita Inc(DVA)的總體評級為持有,目標價格為138.587。

DaVita Inc(DVA)股票的每股收益(EPS TTM)是多少

DaVita Inc(DVA)股票的每股收益(EPS TTM)是9.921。
KeyAI